Bolt Biotherapeutics, Inc. (BOLT)
NCM · Biotechnology
Sources: Yahoo Finance (quote, statistics) · SEC EDGAR (filings, insider trades, 13F holders) · company filings & press wires
Company overview
Bolt Biotherapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company offers product candidates and platform technologies, including PRA-216, BDC-4182, a Boltbody ISAC that targets the tumor-associated antigen claudin 18.2 for the treatment of gastric/gastroesophageal junction cancer, pancreatic cancer, and other tumor types; BDC-3042, a dectin-2 agonist antibody program for the treatment of non-small cell lung cancer, melanoma, and other solid tumors; the Boltbody Immune-Stimulating Antibody Conjugate (ISAC) platform, and the INSPIRE platform. It serves patients, clinical investigators, and biopharmaceutical partners. The company is based in Redwood City, California.
Peers in Biotechnology
All in industry →Vertex Pharmaceuticals Incorporated
Regeneron Pharmaceuticals, Inc.
argenx SE
Alnylam Pharmaceuticals, Inc.
BeOne Medicines AG
Insmed Incorporated
Royalty Pharma plc
BioNTech SE
Roivant Sciences Ltd.
Moderna, Inc.
Recent press releases
Bolt Biotherapeutics, Inc. has not issued a press release in this window.
SEC filings
All filings →Bolt Biotherapeutics, Inc. has not filed an SEC document in this window.
Insider trades
All insider trades →Bolt Biotherapeutics, Inc. has no reported insider trades in the last 90 days.